Literature DB >> 1477227

Evaluation of new anti-infective drugs for the treatment of infections of prosthetic hip joints. Infectious Diseases Society of America and the Food and Drug Administration.

C Norden1, J D Nelson, J T Mader, G B Calandra.   

Abstract

Infections of a prosthetic hip are of three types: acute contiguous, chronic contiguous, and hematogenous. Acute contiguous infections result from contamination of the operative field at the time of surgery; clinical manifestations of infection become apparent within 6 months. Chronic contiguous infections are diagnosed 6-24 months postoperatively and are believed to be caused by intraoperative contamination. Hematogenous seeding of prosthetic joints accounts for infections that develop > or = 2 years after surgery. Fever and pain or dysfunction of the joint may be the only signs or symptoms of prosthetic hip joint infection. Definitive diagnosis is established by culture of a needle aspirate from the joint space or by intraoperative culture. Prospective, randomized, double-blind or evaluator-blinded, active-control comparative studies are preferable to open trials. Success rates 10-14 weeks after completion of a 4- to 6-week course of antimicrobial therapy should be > or = 90%.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477227     DOI: 10.1093/clind/15.supplement_1.s177

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.

Authors:  A C Crémieux; A S Mghir; R Bleton; M Manteau; N Belmatoug; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.

Authors:  Azzam Saleh-Mghir; Nourdine Ameur; Claudette Muller-Serieys; Farid Ismael; Françoise Lemaitre; Laurent Massias; Céline Feger; Rémy Bléton; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

3.  Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.

Authors:  A Saleh Mghir; A C Crémieux; R Bleton; F Ismael; M Manteau; S Dautrey; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

4.  [Diagnosis of chronic osteitis of the bones in the extremities. Relative value of F-18 FDG-PET].

Authors:  M Goebel; F Rosa; K Tatsch; A Grillhoesl; G O Hofmann; M H Kirschner
Journal:  Unfallchirurg       Date:  2007-10       Impact factor: 1.000

5.  Population study evaluating fracture risk among patients with chronic osteomyelitis.

Authors:  Chyi Lo; Fung-Chang Sung; Chih-Hsin Mou; Tzu-Chieh Lin; Chun-Huang Tseng; Ya-Ling Tzeng
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

6.  Ceramic composite with gentamicin decreases persistent infection and increases bone formation in a rat model of debrided osteomyelitis.

Authors:  Aleksey Dvorzhinskiy; Giorgio Perino; Robert Chojnowski; Marjolein C H van der Meulen; Mathias P G Bostrom; Xu Yang
Journal:  J Bone Jt Infect       Date:  2021-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.